文献速递骨软组织肉瘤与黑色素瘤

维莫非尼治疗3219例BRAFV600突变阳性转移性黑色素瘤患者的开放标签多中心安全性研究:2年随访数据及长期缓解者分析

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
PubMed 文献 · Eur J Cancer · 2017-05-11

这项开放标签多中心研究评估维莫非尼(960 mg bid)治疗3219例BRAF V600突变阳性转移性黑色素瘤患者的安全性,中位随访32.2个月(95% CI 31.1-33.2个月),96%患者停药,不良事件与既往报告一致,长期暴露未观察到新的安全性信号,长期缓解者更易发生3/4级不良事件。

要点

  • 中位随访32.2个月,3079/3219例(96%)患者停药,安全性维持。
  • 最常见全等级治疗相关不良事件为关节痛(37%)、脱发(25%)和角化过度(23%)。
  • 最常见3/4级治疗相关不良事件为皮肤鳞状细胞癌(8%)和角化棘皮瘤(8%)。

核心结论

  • 2年随访后,在这组较典型临床试验人群更能代表常规临床实践的BRAFV600突变阳性转移性黑色素瘤患者中,安全性得以维持,长期维莫非尼治疗有效且可耐受,未出现新的安全性信号。

研究设计与样本

  • 开放标签、多中心研究,纳入既往治疗或未治疗的BRAF突变阳性转移性黑色素瘤患者,维莫非尼960 mg bid口服,主要终点为安全性,疗效终点为次要终点,并对缓解持续时间(DOR)≥12或≥24个月的患者进行探索性安全性分析。

主要发现

  • 中位随访32.2个月(95% CI 31.1-33.2个月)后,3079/3219例患者(96%)已停止治疗。
  • 最常见全等级治疗相关不良事件为关节痛(37%)、脱发(25%)和角化过度(23%)。
  • 最常见3/4级治疗相关不良事件为皮肤鳞状细胞癌(8%)和角化棘皮瘤(8%)。
  • 探索性分析中,DOR≥12个月(n=287)或≥24个月(n=133)的患者比总体人群更易发生3/4级不良事件。
  • 更长时间维莫非尼暴露未观察到新的特定安全性信号。

关键数值与推荐

  • 维莫非尼给药方案为960 mg bid。
  • BRAF突变检测采用cobas® 4800 BRAF V600突变检测。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable treatment option for patients with metastatic melanoma harbouring BRAFV600 mutations. We assessed the safety of vemurafenib in a large population of patients with few alternative treatment options; we report updated 2-year safety. METHODS: This was an open-label, multicentre study of vemurafenib (960 mg bid) in patients with previously treated or untreated BRAF mutation-positive metastatic melanoma (cobas® 4800 BRAF V600 Mutation Test). The primary end-point was safety; efficacy end-points were secondary. An exploratory analysis was performed to assess safety outcomes in patients with long duration of response (DOR) (≥12 or ≥24 months). RESULTS: After a median follow-up of 32.2 months (95% CI, 31.1-33.2 months), 3079/3219 patients (96%) had discontinued treatment. Adverse events (AEs) were largely consistent with previous reports; the most common all-grade treatment-related AEs were arthralgia (37%), alopecia (25%) and hyperkeratosis (23%); the most common grade 3/4 treatment-related AEs were squamous cell carcinoma of the skin (8%) and keratoacanthoma (8%). In the exploratory analysis, patients with DOR ≥12 months (n = 287) or ≥24 months (n = 133) were more likely to experience grade 3/4 AEs than the overall population. No new specific safety signals were observed with longer vemurafenib exposure. CONCLUSIONS: After 2 years' follow-up, safety was maintained in this large group of patients with BRAFV600 mutation-positive metastatic melanoma who are more representative of routine clinical practice than typical clinical trial populations. These data suggest that long-term vemurafenib treatment is effective and tolerable without the development of new safety signals.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Blank CU, Larkin J, Arance AM, et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. Eur J Cancer. 2017. PMID: 28501764. doi:10.1016/j.ejca.2017.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。